The European Medicines Agency (EMA) has highlighted ongoing shortages of glucagon-like peptide 1 receptor (GLP-1) agonists, including semaglutide (marketed as Wegovy and Ozempic), as a significant public health challenge likely to persist throughout 2024. Speaking at a recent briefing addressing EU strategies to manage these shortages, EMA’s executive director, Emer Cooke, emphasized, “Despite our collective efforts, the shortages persist, and we do not anticipate resolution this year.”
Login to read more
